Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum

45Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The yeast Saccharomyces boulardii is a biotherapeutic agent used for the prevention and treatment of several gastrointestinal diseases, such as diarrhoea caused by Clostridium difficile, in addition to the antibiotic therapy. In this study we report a case of Saccharomyces cerevisiae fungemia in a patient with Clostridium difficile-associated diarrhoea (CDAD) treated orally with S. boulardii in association with vancomycin. The identification of the S. cerevisiae was confirmed by molecular technique. Fungemia is a rare, but a serious complication to treatment with probiotics. We believe it is important to remind the clinicians of this risk when prescribing probiotics, especially to immunocompromised patients. Copyright © by BIOLIFE, s.a.s.

Cite

CITATION STYLE

APA

Santino, I., Alari, A., Bono, S., Teti, E., Marangi, M., Bernardini, A., … Teggi, A. (2014). Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. International Journal of Immunopathology and Pharmacology, 27(1), 143–146. https://doi.org/10.1177/039463201402700120

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free